Difference between revisions of "Interferon alfa-2a (Roferon-A)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "http://hemonc.org" to "https://hemonc.org")
(10 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.<ref name="insert">[http://www.gene.com/gene/products/information/roferon-a/pdf/pi.pdf Interferon alfa-2a (Roferon-A) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/interferonalfa-2a.pdf Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.<ref name="insert">[http://www.gene.com/gene/products/information/roferon-a/pdf/pi.pdf Interferon alfa-2a (Roferon-A) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/interferonalfa-2a.pdf Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)]</ref>
 
<br>Route: SC
 
<br>Route: SC
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Chronic myeloid leukemia]]
 +
*[[Hairy cell leukemia]]
 +
*[[Renal cell carcinoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Chronic myelogenous leukemia]]
 
−
*[[Hairy cell leukemia]]
 
 
*[[Kaposi sarcoma]]
 
*[[Kaposi sarcoma]]
 
*[[Neuroendocrine tumor]]
 
*[[Neuroendocrine tumor]]
−
*[[Renal cell carcinoma]]
 
 
*[[Cutaneous squamous cell carcinoma]]
 
*[[Cutaneous squamous cell carcinoma]]
  
Line 24: Line 26:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*6/4/1986: Initial FDA approval for treatment of patients 18 years of age or older with [[hairy cell leukemia]]
+
*1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with [[hairy cell leukemia]] ''(Based on N2752)''
−
*Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive [[chronic myelogenous leukemia|chronic myelogenous leukemia (CML)]] patients who are minimally pretreated (within 1 year of diagnosis).
+
*Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive [[Chronic myeloid leukemia|chronic myelogenous leukemia (CML)]] patients who are minimally pretreated (within 1 year of diagnosis). ''(Based on DM 84-38 & MI400)''
  
 
==Also known as==
 
==Also known as==
Line 35: Line 37:
 
[[Category:Drugs]]
 
[[Category:Drugs]]
 
[[Category:Subcutaneous medications]]
 
[[Category:Subcutaneous medications]]
−
[[Category:Interferon alfa]]
+
[[Category:Interferon alfas]]
  
−
[[Category:Chronic myelogenous leukemia medications]]
+
[[Category:Chronic myeloid leukemia medications]]
 
[[Category:Hairy cell leukemia medications]]
 
[[Category:Hairy cell leukemia medications]]
 
[[Category:Kaposi sarcoma medications]]
 
[[Category:Kaposi sarcoma medications]]

Revision as of 19:29, 23 June 2024

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia (Based on N2752)
  • Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis). (Based on DM 84-38 & MI400)

Also known as

  • Brand name: Laroferon, Roferon-A

References

  1. ↑ 1.0 1.1 1.2 Interferon alfa-2a (Roferon-A) package insert
  2. ↑ Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)
  3. ↑ Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)
Retrieved from "https://hemonc.org/w/index.php?title=Interferon_alfa-2a_(Roferon-A)&oldid=86566"